What is Global Neuroendocrine Tumor Treatment Market?
The Global Neuroendocrine Tumor Treatment Market is a specialized sector within the healthcare industry that focuses on the treatment of neuroendocrine tumors. These tumors are rare and can occur anywhere in the body where there are neuroendocrine cells. They are most commonly found in the lungs, pancreas, and gastrointestinal tract. The market encompasses various treatment methods, including surgery, radiation therapy, chemotherapy, and targeted therapy. The value of this market was estimated at US$ 1495.4 million in 2023 and is projected to reach US$ 2302.3 million by 2030. This growth is driven by an increase in the prevalence of neuroendocrine tumors, advancements in diagnostic techniques, and the development of novel treatment options.
Everolimus, Sunitinib, Lu-Dotatate, Lanreotide, Octreotide in the Global Neuroendocrine Tumor Treatment Market:
The Global Neuroendocrine Tumor Treatment Market includes several key players and treatments. Everolimus and Sunitinib are two drugs that inhibit the growth of tumor cells by blocking certain enzymes. Lu-Dotatate is a type of peptide receptor radionuclide therapy (PRRT) that delivers radiation directly to the tumor cells. Lanreotide and Octreotide are somatostatin analogues that can help control symptoms in patients with neuroendocrine tumors. These treatments have shown effectiveness in managing neuroendocrine tumors and have significantly contributed to the growth of the market.
Hospitals, Clinic, Others in the Global Neuroendocrine Tumor Treatment Market:
The Global Neuroendocrine Tumor Treatment Market is utilized in various healthcare settings, including hospitals, clinics, and other medical facilities. In hospitals, these treatments are often used in conjunction with other therapies to manage neuroendocrine tumors. Clinics may offer more specialized care, focusing on the diagnosis and treatment of these tumors. Other facilities, such as research institutions, may use these treatments in clinical trials to develop and test new therapies. The use of these treatments in different settings allows for a comprehensive approach to managing neuroendocrine tumors.
Global Neuroendocrine Tumor Treatment Market Outlook:
The outlook for the Global Neuroendocrine Tumor Treatment Market is promising. In 2023, the market was valued at US$ 1495.4 million and is expected to reach US$ 2302.3 million by 2030, reflecting a CAGR of 5.9%. This growth is in line with the overall expansion of the global pharmaceutical market, which is projected to grow at a CAGR of 5% over the next six years. The chemical drug market, a subset of the pharmaceutical market, is also expected to see growth, increasing from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. These trends indicate a positive trajectory for the Global Neuroendocrine Tumor Treatment Market.
| Report Metric | Details |
| Report Name | Neuroendocrine Tumor Treatment Market |
| Accounted market size in 2023 | US$ 1495.4 million |
| Forecasted market size in 2030 | US$ 2302.3 million |
| CAGR | 5.9% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
